MTAP and non-small cell lung carcinoma: For example, MRTX1719 has demonstrated potent antitumor activity in preclinical models of MTAP-deficient cancers and has shown objective responses in phase I/II trials for melanoma, gallbladder adenocarcinoma, mesothelioma, non-small cell lung cancer, and malignant peripheral nerve sheath tumors (NCT06672523, NCT05245500) [575, 576].